Tier 2 Professors

undefined

WANG Liwei

M.D. and Ph.D., Professor, Chief physician, Doctor's Supervisor

Email: Liweiwang@shsmu.edu.cn

Tel: 021-

Research interest: Precise diagnosis and treatment of pancreatic cancer and multiple primary malignances

Biography

  • Liwei Wang, M.D. and Ph.D. in Oncology from Nanjing Medical University. He is the professor and chairman of department of Oncology and Comprehensive Pancreatic Cancer Center, Renji Hospital, Shanghai Jiao Tong University. He was the chairman of the first Chinese Society of Clinical Oncology (CSCO) Pancreatic Cancer Expert Committee. He is also the chairman of MDT Expert Committee of Renji Hospital and chairman of Pancreatic Cancer Expert Committee of CSCO Chair, Group of Pancreatic Oncology, Committee of Oncology Branch of Chinese Medical Association. He presided over the first “Chinese Expert Consensus on the Diagnosis and Treatment of Pancreatic Cancer” and the first “CSCO Guidelines for Pancreatic Cancer Diagnosis and Treatment”. Since 1990, he has specialized in clinical work, teaching and scientific research of oncology. He has participated in the completion of more than 20 national, provincial and departmental projects. He has presided over and completed 6 projects of National Natural Science Foundation of China. His main research areas are conducting clinical trials concerning targeted therapy and immunotherapy for solid tumors especially gastrointestinal tumors and first-in-class drugs development; conducting multidisciplinary cancer management for gastrointestinal tumors patients to improve their outcomes; using multi-omics analysis to clarify clinical pattern and identify new therapeutic targets of pancreatic cancer; investigating the molecular mechanism and clinical characteristic of pancreatic cancer and multiple primary malignances.

Publications

Appendix: Papers of the first author or corresponding author included in SCI in recent years:

  1. Zhang X, Mao T, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Ge W, Li S, Yue M, Ma J, Yao J, Wang Y, Wang Y, Shentu D, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L, Wang L. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. EBioMedicine. 2022 Mar;77:103897.

  2. Xue S, Ge W, Wang K, Mao T, Zhang X, Xu H, Wang Y, Yao J, Li S, Yue M, Ma J, Wang Y, Shentu D, Cui J, Wang L. Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Front Cell Dev Biol. 2022 Aug 8;10:942225.

  3. Ge W, Ma J, Mao T, Xu H, Zhang X, Li S, Wang Y, Yao J, Yue M, Jiao F, Wang Y, Zhuo M, Han T, Hu J, Zhang X, Cui J, Wang L. Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer. Front Oncol. 2022 Jun 8;12:890715.

  4. Wang Y, Liang Y, Xu H, Zhang X, Mao T, Cui J, Yao J, Wang Y, Jiao F, Xiao X, Hu J, Xia Q, Zhang X, Wang X, Sun Y, Fu D, Shen L, Xu X, Xue J, Wang L. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response [J]. Cell Discov. 2021 May 25;7(1):36.

  5. Cui J, Yang H, Liu J, Chen D, Hu J, Zhang H, Wang Y, Han T, Mao T, Jiao F, Biskup E, Pan Y, Liu M, Wang L. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer. 2021 Jun 7;21(1):672.

  6. Yang H, Hu J, Chen J, Chen Z, Jiao F, Cui J, Quan M, Wang L. RNA-binding protein Musashi2 regulates Hippo signaling via SAV1 and MOB1 in pancreatic cancer. Med Oncol. 2020 Aug 11;37(9):84.

  7. Han T, Zhuo M, Yuan C, Xiao X, Cui J, Qin G, Wang L, Jiao F. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma. Cancer Biol Med. 2020 Nov 15;17(4):953-969.

  8. Jiao F, Han T, Yuan C, Liang Y, Cui J, Zhuo M, Wang L: Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer. Cancer Cell Int 2020, 20:55.

  9. Quan M, Chen Z, Jiao F, Xiao X, Xia Q, Chen J, Chao Q, Li Y, Gao Y, Yang H, Wang L, Cui J. Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression [J]. J Exp Clin Cancer Res. 2020 Jan 15;39(1):13.

  10. Lu P, Geng J, Zhang L, Wang Y, Niu N, Fang Y, Liu F, Shi J, Zhang ZG, Sun Y, Wang L*, Xue J*: THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Oncogene 2019, 38(20):3932-3945.

  11. Cui J, Zhou Z, Yang H, Jiao F, Li N, Gao Y, Wang L, Chen J, Quan M. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis. Mol Cancer Res. 2019 Jun;17(6):1316-1325.

  12. Zhuo M, Yuan C, Han T, Hu H, Cui J, Jiao F, Wang L. JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1/2-MMP-2/9 signaling pathway both in vitro and in vivo. Am J Transl Res. 2019 Feb 15;11(2):1030-1039.

  13. Zhuo M, Yuan C, Han T, Cui J, Jiao F, Wang L. A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis. BMC Cancer. 2018 Oct 23;18(1):1032.

  14. Hu H, Li H, Jiao F, Han T, Zhuo M, Cui J, Li Y, Wang L. Association of a novel point mutation in MSH2 gene with familial multiple primary cancers. J Hematol Oncol. 10(1):158, 2017.

  15. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 34:1448-1454, 2016.

  16. Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, Guo Z, Wang L. Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci. 2015 Mar 24;16(4):6677-93.

  17. Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, Guo Z, Wang L. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep. 2014 Dec;32(6):2485-92.